☰

Alison M. Kurimchak, Ph.D. - Publications

Affiliations: 
2014 Molecular Biology and Genetics Temple University, Philadelphia, PA, United States 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Jermakowicz AM, Kurimchak AM, Johnson KJ, Bourgain-Guglielmetti F, Kaeppeli S, Affer M, Pradhyumnan H, Suter RK, Walters W, Cepero M, Duncan JS, Ayad NG. RAPID resistance to BET inhibitors is mediated by FGFR1 in glioblastoma. Scientific Reports. 14: 9284. PMID 38654040 DOI: 10.1038/s41598-024-60031-8  0.322
2024 Cannon AC, Budagyan K, Uribe-Alvarez C, Kurimchak AM, Araiza-Olivera D, Cai KQ, Peri S, Zhou Y, Duncan JS, Chernoff J. Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Oncogene. PMID 38243078 DOI: 10.1038/s41388-024-02947-z  0.389
2023 Baqai U, Kurimchak AM, Trachtenberg I, Purwin TJ, Haj JI, Han A, Luo K, Pachon NF, Jeon A, Chua V, Davies MA, Gutkind JS, Benovic JL, Duncan JS, Aplin AE. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma. The Journal of Biological Chemistry. 105418. PMID 37923138 DOI: 10.1016/j.jbc.2023.105418  0.433
2023 Cannon AC, Budagyan K, Uribe-Alvarez C, Kurimchak AM, Araiza-Olivera D, Cai KQ, Peri S, Zhou Y, Duncan JS, Chernoff J. Unique vulnerability of -mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Biorxiv : the Preprint Server For Biology. PMID 37425776 DOI: 10.1101/2023.06.27.546707  0.383
2022 Kurimchak AM, Herrera-Montávez C, Montserrat-Sangrà S, Araiza-Olivera D, Hu J, Neumann-Domer R, Kuruvilla M, Bellacosa A, Testa JR, Jin J, Duncan JS. The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells. Science Signaling. 15: eabn2707. PMID 36041010 DOI: 10.1126/scisignal.abn2707  0.341
2022 Tang B, Lee HO, Gupta S, Wang L, Kurimchak AM, Duncan JS, Kruger WD. Extracellular 5'-methylthioadenosine inhibits intracellular symmetric dimethylarginine protein methylation of FUSE-element binding proteins. The Journal of Biological Chemistry. 102367. PMID 35963436 DOI: 10.1016/j.jbc.2022.102367  0.323
2020 Kurimchak AM, Kumar V, Herrera-Montávez C, Johnson KJ, Srivastava N, Davarajan K, Peri S, Cai KQ, Mantia-Smaldone GM, Duncan JS. Kinome Profiling of Primary Endometrial Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies SRPK1 as Candidate Therapeutic Target. Molecular & Cellular Proteomics : McP. 19: 2068-2090. PMID 33451638 DOI: 10.1074/mcp.RA120.002012  0.428
2020 Kurimchak AM, Kumar V, Herrera-Montávez C, Johnson KJ, Srivastava N, Devarajan K, Peri S, Cai KQ, Mantia-Smaldone GM, Duncan JS. Kinome Profiling of Primary Endometrial Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies SRPK1 As Candidate Therapeutic Target. Molecular & Cellular Proteomics : McP. PMID 32994315 DOI: 10.1074/mcp.RA120.002012  0.424
2020 Kurimchak AM, Herrera-Montávez C, Brown J, Johnson KJ, Sodi V, Srivastava N, Kumar V, Deihimi S, O'Brien S, Peri S, Mantia-Smaldone GM, Jain A, Winters RM, Cai KQ, Chernoff J, et al. Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma. Science Signaling. 13. PMID 32071169 DOI: 10.1126/Scisignal.Aax8238  0.471
2020 Srivastava N, Kurimchak A, Montavez C, Chernoff J, Duncan J. Abstract A34: Defining KRAS mutation-specific kinome signatures and vulnerabilities in colorectal cancer Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Ras18-A34  0.351
2019 Zhao Z, Kurimchak A, Nikonova AS, Feiser F, Wasserman JS, Fowle H, Varughese T, Connors M, Johnson K, Makhov P, Lindskog C, Kolenko VM, Golemis EA, Duncan JS, Graña X. PPP2R2A prostate cancer haploinsufficiency is associated with worse prognosis and a high vulnerability to B55α/PP2A reconstitution that triggers centrosome destabilization. Oncogenesis. 8: 72. PMID 31822657 DOI: 10.1038/s41389-019-0180-9  0.368
2019 Kurimchak AM, Shelton C, Herrera-Montávez C, Duncan KE, Chernoff J, Duncan JS. Intrinsic Resistance to MEK Inhibition Through BET Protein Mediated Kinome Reprogramming in NF1-deficient Ovarian Cancer. Molecular Cancer Research : McR. PMID 31043489 DOI: 10.1158/1541-7786.Mcr-18-1332  0.415
2017 Zhao Z, Kurimchak A, Makhov P, Johnson K, Kolenko V, Duncan J, Graña X. Abstract LB-320: Reconstituting B55/protein phosphatase 2A activity in B55/PP2A-defective prostate cancer cells suppresses proliferation and tumorigenicity through pleiotropic mechanisms Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-320  0.443
2016 Kurimchak AM, Shelton C, Duncan KE, Johnson KJ, Brown J, O'Brien S, Gabbasov R, Fink LS, Li Y, Lounsbury N, Abou-Gharbia M, Childers WE, Connolly DC, Chernoff J, Peterson JR, et al. Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Reports. PMID 27452461 DOI: 10.1016/J.Celrep.2016.06.091  0.413
2016 Zhao Z, kurimchak A, Adeyemi M, Woodruff P, Kolenko V, Graña X. Abstract 3662: Analysis of the tumor suppressor function of B55alpha, the PP2A regulatory subunit encoded by PPP2R2A, in prostate cancer cells Cancer Research. 76: 3662-3662. DOI: 10.1158/1538-7445.Am2016-3662  0.468
2015 Kurimchak A, Graña X. PP2A: more than a reset switch to activate pRB proteins during the cell cycle and in response to signaling cues. Cell Cycle (Georgetown, Tex.). 14: 18-30. PMID 25483052 DOI: 10.4161/15384101.2014.985069  0.484
2013 Kurimchak A, Haines DS, Garriga J, Wu S, De Luca F, Sweredoski MJ, Deshaies RJ, Hess S, Graña X. Activation of p107 by fibroblast growth factor, which is essential for chondrocyte cell cycle exit, is mediated by the protein phosphatase 2A/B55α holoenzyme. Molecular and Cellular Biology. 33: 3330-42. PMID 23775125 DOI: 10.1128/Mcb.00082-13  0.389
2012 Kurimchak A, Graña X. PP2A Counterbalances Phosphorylation of pRB and Mitotic Proteins by Multiple CDKs: Potential Implications for PP2A Disruption in Cancer. Genes & Cancer. 3: 739-48. PMID 23634261 DOI: 10.1177/1947601912473479  0.495
2012 Kurimchak A, Graña X. PP2A holoenzymes negatively and positively regulate cell cycle progression by dephosphorylating pocket proteins and multiple CDK substrates. Gene. 499: 1-7. PMID 22387205 DOI: 10.1016/J.Gene.2012.02.015  0.471
2010 Jayadeva G, Kurimchak A, Garriga J, Sotillo E, Davis AJ, Haines DS, Mumby M, Graña X. B55alpha PP2A holoenzymes modulate the phosphorylation status of the retinoblastoma-related protein p107 and its activation. The Journal of Biological Chemistry. 285: 29863-73. PMID 20663872 DOI: 10.1074/Jbc.M110.162354  0.494
2009 Sotillo E, Garriga J, Padgaonkar A, Kurimchak A, Cook JG, Graña X. Coordinated activation of the origin licensing factor CDC6 and CDK2 in resting human fibroblasts expressing SV40 small T antigen and cyclin E. The Journal of Biological Chemistry. 284: 14126-35. PMID 19321444 DOI: 10.1074/Jbc.M900687200  0.401
2008 Sotillo E, Garriga J, Kurimchak A, Graña X. Cyclin E and SV40 small T antigen cooperate to bypass quiescence and contribute to transformation by activating CDK2 in human fibroblasts. The Journal of Biological Chemistry. 283: 11280-92. PMID 18276582 DOI: 10.1074/Jbc.M709055200  0.465
Show low-probability matches.